TRASTUZUMAB DERUXTECAN
UNII 5384HK7574

Substance Identification & Data

This profile provides standardized clinical and technical data for Trastuzumab Deruxtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 5384HK7574.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1826843-81-5 and the RxNorm Concept ID (RxCUI) 2267582. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

5384HK7574

CAS Registry Number

1826843-81-5

RxNorm Concept ID

2267582

Detailed Substance Profile

Preferred Name

TRASTUZUMAB DERUXTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

5384HK7574

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C128799

National Cancer Institute reference terminology for clinical and research data.

INN ID

10516

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

GH-79

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trastuzumab Deruxtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

FAM-TRASTUZUMAB DERUXTECAN-NXKI

TRASTUZUMAB DERUXTECAN

Common Names & Synonyms

TRASTUZUMAB DERUXTECAN [INN]

TRASTUZUMAB DERUXTECAN [JAN]

TRASTUZUMAB DERUXTECAN [USAN]

TRASTUZUMAB DERUXTECAN [WHO-DD]

TRASTUZUMAB DERUXTECAN NXKI [WHO-DD]

TRASTUZUMAB DERUXTECAN-NXKI

Brand / Trade Names

ENHERTU

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN TYROSINE KINASE RECEPTOR ERBB2) (HUMAN-MUS MUSCULUS MONOCLONAL DS20151130 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL DS20151130 LIGHT CHAIN, DIMER, THIOETHER WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)GLYCYLGLYCYL-L-PHENYLALANYL-N-((2-(((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-2-OXOETHOXY)METHYL)GLYCINAMIDE

SYS

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (METASTATIC LYMPH NODE GENE 19 PROTEIN, PROTO-ONCOGENE C-ERBB-2, CD340 ANTIGEN))HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO DERUXTECAN, A CAMPTOTHECIN DERIVATIVE AND A LINKER.GAMMA.1 HEAVY CHAIN (1-450) (HUMANIZED VH (HOMO SAPIENS IGHV3-66*01 (82%) (IGHD)-IGHJ4*02) (8.8.13) (1-120)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(217)) (121-450)) (223-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-214') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (86%) IGKJ1*01)(6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (229-229'':232-232'')-BISDISULFIDE, AN AVERAGE OF 8 CYSTEIN RESIDUES ARE NOT INVOLVED IN DISULFIDE BRIDGE AND S SUBSTITUTED WITH (3RS)-1-((10S)-10-BENZYL-1-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-1,6,9,12,15,18-HEXAOXO-3-OXA-5,8,11,14,17-PENTAAZATRICOSAN-23-YL)-2,5-DIOXOPYRROLIDIN-3-YL

SYS